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Fibronectin is an abundant adhesive glycoprotein that is evolutionarily conserved and broadly distributed among vertebrates (1). The polymerization of soluble fibronectin into insoluble fibrils within the ECM3 is a dynamic, cell-dependent
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process that is mediated by coordinate events involving the
actin cytoskeleton and integrin receptors (2). Previous studies
have shown that active fibronectin matrix polymerization promotes cellular functions critical for tissue repair, including cell
growth (3– 6), cell migration (7), and collagen matrix contraction (8). Fibronectin matrix polymerization also promotes collagen I deposition (9, 10) and enhances the tensile strength of
collagen-based tissue constructs (11); integrin ligation alone is
not sufficient to trigger these responses (3, 7–9, 11). The mechanism by which ECM fibronectin exerts its unique effect on cell
function is only partially understood.
In the ECM, fibronectin is organized as an extensive network
of elongated, branching fibrils. Time lapse microscopy of cells
expressing green fluorescent protein-labeled fibronectin demonstrate that cells routinely stretch ECM fibronectin into long
fibrillar strands that recoil when released (12). The three-dimensional organization of ECM fibronectin likely arises from
the ability of cells to repeatedly exert a mechanical force (13) on
discrete regions of the protein (14) to facilitate the formation of
fibronectin-fibronectin interactions (15–19). As cells contact
fibronectin fibrils, tractional forces induce additional conformational changes (20) that are necessary for both lateral growth
and branching of the fibrils (17).
Fibronectin, like many other ECM molecules, is a mosaic
protein composed of modular subunits (21). The primary structure of each subunit is organized into three types of repeating
homologous units, termed types I, II, and III. Fibronectin type
III repeats (FNIII) are found in a number of ECM proteins and
consist of seven ␤-strands that overlap to form two ␤-sheets
(22, 23). Molecular modeling and atomic force microscopy
studies predict that reversible unfolding of the type III repeats
contributes to the elasticity of fibronectin, which may be
extended up to six times its initial length (14, 24, 25). Fibronectin modules contain multiple binding sites, including those for
glycosaminoglycans, collagen or gelatin, fibrin, and integrin
receptors; additional binding sites may become available as
fibronectin modules are elongated and internal residues are
exposed (18, 25, 26).
The anti-parallel ␤-sheets of FNIII repeats are composed of
three (A, B, and E) and four (C, D, F, and G) ␤-strands. Proteolysis of the first type III repeat of fibronectin (FNIII1) at residue
Ile597 removes both the A and B ␤-strands and results in a
C-terminal fragment that binds to heparin (27). FNIII1 also
exhibits cryptic homophilic binding activity (18, 28) that mediates fibronectin fibril formation (16, 29). These sites are not
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Fibronectins are high molecular mass glycoproteins that circulate as soluble molecules in the blood, and are also found in an
insoluble, multimeric form in extracellular matrices throughout
the body. Soluble fibronectins are polymerized into insoluble
extracellular matrix (ECM) fibrils via a cell-dependent process.
Recent studies indicate that the interaction of cells with the
ECM form of fibronectin promotes actin organization and cell
contractility, increases cell growth and migration, and enhances
the tensile strength of artificial tissue constructs; ligation of
integrins alone is insufficient to trigger these responses. Evidence suggests that the effect of ECM fibronectin on cell function is mediated in part by a matricryptic heparin-binding site
within the first III1 repeat (FNIII1). In this study, we localized
the heparin-binding activity of FNIII1 to a cluster of basic amino
acids, Arg613, Trp614, Arg615, and Lys617. Site-directed mutagenesis of a recombinant fibronectin construct engineered to mimic
the ECM form of fibronectin demonstrates that these residues
are also critical for stimulating cell spreading and increasing cell
proliferation. Cell proliferation has been tightly correlated with
cell area. Using integrin- and heparin-binding fibronectin
mutants, we found a positive correlation between cell spreading
and growth when cells were submaximally spread on ECM protein-coated surfaces at the time of treatment. However, cells
maximally spread on vitronectin or fibronectin still responded
to the fibronectin matrix mimetic with an increase in growth,
indicating that an absolute change in cell area is not required for
the increase in cell proliferation induced by the matricryptic site
of FNIII1.

Heparin-binding and Growth Activities of Fibronectin III1

EXPERIMENTAL PROCEDURES
Reagents—Human plasma fibronectin was isolated from
Cohn’s fraction I and II, as described previously (33). Human
plasma vitronectin was a gift from Dr. Scott Blystone (SUNY
Upstate Medical University, Syracuse, NY). Human fibrinogen
was a gift from Dr. Patricia Simpson-Haidaris (University of
Rochester, Rochester, NY). Laminin was from BD Biosciences.
Type I rat tail collagen was obtained from Upstate (Lake Placid,
NY). Fibronectin III1 peptides were from Sigma. Antibodies
and their sources are as follows: anti-FNIII1 IgG (9D2 (29)), a
gift from Dr. Deane Mosher, University of Wisconsin, Madison,
WI; mouse IgG Cappel, Aurora, OH; anti-GST polyclonal IgG,
Upstate; horseradish peroxidase-conjugated goat anti-mouse
and anti-rabbit antibodies, Bio-Rad. Tissue culture supplies
were obtained from Corning/Costar (Cambridge, MA). Unless
otherwise indicated, chemical reagents were from Sigma.
Cell Culture—Mouse embryonic FN-null MFs (3) were generously provided by Dr. Jane Sottile (University of Rochester,
Rochester, NY). FN-null MFs do not produce endogenous
fibronectin but are able to polymerize exogenously added
fibronectin into the ECM (3). FN-null MFs were cultured on
collagen I-coated dishes under serum-free conditions using a
1:1 mixture of Cellgro威 (Mediatech, Herndon, VA) and Aim V
(Invitrogen). These media do not require serum supplementation. Thus, no exogenous source of fibronectin is present during routine culture.
NOVEMBER 17, 2006 • VOLUME 281 • NUMBER 46

Recombinant Fibronectins—Recombinant GST/III1H, GST/
III1H,8 –10, GST/III1H,2–4, GST/III8–10, and GST/III8–10,13
were produced in bacteria and purified as described previously
(32). FNIII1H is comprised of amino acids Ile597–Thr673 (bases
1802–2032). The FNIII1H,8–10 heparin-binding mutant (GST/
III1H,8–10⌬KRWRK; K609G,R613T,W614T,R615T,K617A)
was produced using the following mutant sense primer: 5⬘CCCGGTACCATCCAGTGGAATGCACCACAGCCATCTCACATTTCCGGGTACATTCTCACGACGACACCTGCAAATTCTGTAGGC. Mutations are underlined; a Kpn
site is shown in bold. The mutant sense primer for GST/
III1H,8 –10⌬RWR (R613T,W614T,R615T) (5⬘-CCCGGTACCATCCAGTGGAATGCACCACAGCCATCTCACATTTCCAAGTACATTCTCACGACGACACCTAAAAATTCTGTAGGC) also contains a Kpn site. The antisense primer
used for both III1H mutants was the same as that used to
amplify GST/III8 –10 (32). The sense primer for GST/
III1H,8 –10RGE (D1495E) (5⬘-CCCGGTACCATCCAGTGGAATGCACCACAG) contains a Kpn site; the antisense
mutant primer (5⬘-CCCCCCGGGCTATGTTCGGTAATTAATGGAAATTGGCTTGCTGCTTGCGGGGCTTTCTCCACGGCCAGTG) contains a SmaI site. GST/III1H,8 –
10⌬Syn (R1374A,R1379A) was produced using the same
mutant inner sense and antisense primers as were used previously to generate GST/III9 –10R1374A,R1379A (32). The
outer primers were the same as those used to amplify GST/
III1H,8 –10RGE (sense) and GST/III8 –10 (antisense) (32).
Purified GST/III1H,8 –10 DNA (32) was used as the PCR
template for all mutant GST/III1H,8 –10 constructs except
GST/III1H,8 –10⌬Syn/RGE. The production of GST/
III1H,8 –10⌬Syn/RGE was similar to that of GST/III1H,8 –
10⌬Syn except that GST/III1H,8 –10RGE DNA was used for
amplification.
The truncated GST/III1 constructs were produced using the
III1 sense primer (5⬘-CCCGGATCCAGTGGTCCTGTCGAAGTATTTAT) containing a BamHI site (bold) and the following
antisense primers: GST/III1F666 (bases 1745–2011; Ser578–
Phe666): 5⬘-CCCGAATTCCTAGAAGTCAAAGCGAGTCACTTC; GST/III1F664 (bases 1745–2005; Ser578–Phe664): 5⬘-CCCGGATCCCTAAAAGCGAGTCACTTCTTGGTG; GST/
III1Y656 (bases 1745–1981; Ser578–Tyr656): 5⬘-CCCGAATTCCTAGTACTGCTGGATGCTGATGAG;
GST/III1Y646
(bases 1745–1951; Ser578–Tyr646): 5⬘-CCCGAATTCCTAGTATACCACACCAGGCTTC. EcoRI sites are shown in bold.
GST/III-1K641T was produced using the following mutant
primers: 5⬘-TCAAAGGCCTGACGCCTGGTGTGGT (sense)
and 5⬘-ACCACACCAGGCGTCAGGCCTTTGA (antisense).
The outer primers were the same as those used to amplify nonmutant GST/III1 (bases 1745–2905; Ser578–Thr673) (18).
PCR-amplified DNA was cloned into pGEX-2T (Amersham
Biosciences) and transfected into DH5␣ bacteria (32). DNA was
sequenced to confirm the presence of the mutations. Fusion
proteins were isolated on glutathione-Sepharose (Amersham
Biosciences) and dialyzed extensively against PBS, as described
previously (18).
Collagen Gel Contraction Assay—Floating type I collagen
gels were prepared as described previously (8). Collagen gels
imbedded with FN-null MFs and FNIII1 peptides were incuJOURNAL OF BIOLOGICAL CHEMISTRY
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exposed in soluble fibronectin (18, 27), but may be exposed
either during fibronectin matrix polymerization or as cells exert
tension on the insoluble matrix (30, 31). We previously hypothesized that the cryptic heparin-binding activity of FNIII1 functions as a conformation-dependent site for cell surface heparan
sulfate proteoglycans (HSPGs) and thus, serves as a mechanism
by which the ECM form of fibronectin exerts its unique effect
on cell function. To test this hypothesis, we developed a GSTtagged fusion protein in which the C-terminal, heparin-binding
fragment of FNIII1, comprised of residues Ile597-Thr673, was
directly linked to the integrin-binding FNIII8 –10 modules
(GST/III1H,8 –10). Treatment of fibronectin-null myofibroblasts (FN-null MFs) with GST/III1H,8 –10 stimulated cell
growth, contractility, and migration to a similar extent as ECM
fibronectin (7, 32). As such, this fibronectin matrix mimetic
effectively bypasses some of the requirements for intact
fibronectin to undergo conformational changes to initiate ECM
fibronectin-specific signals. Here, we used site-directed
mutagenesis of the matrix mimetic to map the heparin-binding,
cell spreading, and growth-promoting activities of FNIII1. We
localized these activities to a cluster of basic amino acids,
Arg613-Trp614-Arg615-Lys617, that are contained within the
C-strand of FNIII1. Using integrin- and heparin-binding
fibronectin mutants, we found a positive correlation between
increased cell spreading and increased cell growth when cell
area at the time of exposure was submaximal. However, cells
maximally spread on vitronectin or fibronectin substrates still
responded to the fibronectin matrix mimetic with an increase
in growth, indicating that an absolute change in cell area is not
required for the increased rate of cell proliferation induced by
ECM fibronectin.

Heparin-binding and Growth Activities of Fibronectin III1
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FIGURE 1. Effect of FNIII1 peptides on collagen gel contraction. Collagen
gel contraction assays were performed on FN-null MFs, as described under
“Experimental Procedures.” A, collagen gels were incubated in the absence
and presence of 500 nM GST/III1H,8 –10 or 100 M of the various FNIII1 peptides. *, significantly different from ⫹PBS, p ⬍ 0.01. B, collagen gels were
treated with increasing concentrations of Peptide 1 or the control, scrambled
(s) Peptide 1. *, significantly different from corresponding dose of sPeptide 1,
p ⬍ 0.01. Peptide sequences are shown in Fig. 3.

RESULTS
Identification of the Matricryptic Heparin-binding Site in
FNIII1—Our previous studies indicate that the effect of ECM
fibronectin on cell function is mediated in part by a matricryptic, heparin-binding site within FNIII1 (7, 32). To further define
the role of FNIII1 in promoting cell growth and contractility,
studies were conducted to localize the functionally active site in
FNIII1. In cell growth and migration assays, the cellular
response to the fibronectin matrix mimetic, GST/III1H,8 –10,
requires both FNIII1H as well as ␣5␤1 integrin ligation via the
FNIII8 –10 modules. In contrast, cell-mediated collagen gel contraction is stimulated by a FNIII1H construct that does not contain an integrin-binding site (32). Thus, overlapping 18-mer
peptides encompassing a cluster of basic residues in FNIII1
were used in collagen gel contraction assays to initially map the
active site in FNIII1H. As shown in Fig. 1A, Peptides 1, 2, and 3,
containing the common sequence, 613RWRPKNSVGR, stimulated collagen gel contraction; Peptide 4 had no effect. Concentrations of Peptide 1 ranging from 250 nM to 25 M produced a
significant increase in collagen gel contraction compared with
the control scrambled Peptide 1 (sPeptide 1; Fig. 1B). The
effects of Peptide 1 on contraction were saturable, reaching a
maximum between 0.5 and 1 M (Fig. 1B). These values are in
agreement with previous studies demonstrating that dimeric
FN, which contains two III1 modules, stimulates maximum collagen gel contraction between 0.2 and 0.4 M (32).
VOLUME 281 • NUMBER 46 • NOVEMBER 17, 2006
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bated for 20 h and then removed from the wells and weighed.
Collagen gel contraction was measured as a decrease in gel
weight (8). Data are reported as percent of contraction: (1 ⫺
weight of the test gels/weight of gels not containing cells) ⫻
100.
Solid-phase Enzyme-linked Immunosorbent Assay and Heparin Binding Assay—Glutathione-coated 96-well plates
(Pierce) were incubated with saturating concentrations of GST
fusion protein, as previously described (32). Plates were then
washed and incubated with either primary antibodies (1 g/ml)
or 5 g/ml heparin-albumin-biotin followed by horseradish
peroxidase-linked secondary antibodies or horseradish peroxidase-NeutrAvidin (Molecular Probes, Eugene, OR). The assays
were developed using 2,2-azino-bis(3-ethylbenzthiazolinesulfonic acid) and the absorbance at 405 nm was measured.
Cell Spreading Assay—Tissue culture dishes (24-well) were
coated with collagen I (50 g/ml in 0.02 N acetic acid (3)),
fibronectin (10 g/ml), vitronectin (1 or 10 g/ml), fibrinogen
(10 g/ml), or laminin (10 g/ml). Proteins other than collagen
were diluted in PBS. FN-null MFs were seeded at 2.7 ⫻ 103
cells/cm2 (34) in defined medium and incubated at 37 °C for 4 h.
Cells were then treated with 20 nM fibronectin, 250 nM GST
fusion proteins, or an equal volume of PBS. At various times,
cells were fixed with 2% paraformaldehyde. Cells were visualized with an Olympus inverted microscope (IX70) using a ⫻40
objective. Phase-contrast images of fixed cells from triplicate
wells were obtained using a Spot digital camera (Diagnostic
Instruments, Sterling Heights, MI). The areas of at least 49 randomly chosen cells per condition were determined using
ImagePro-Plus software (Media Cybernetics, Silver Spring,
MD) calibrated with a stage micrometer.
Cell Growth Assay—FN-null MFs were seeded on tissue culture plates (48-well) coated with collagen, fibronectin, laminin,
fibrinogen, or vitronectin at 3 ⫻ 103 cells/cm2 for 4 h (32). Cells
were then incubated with 250 nM of the various recombinant
fibronectin constructs at 37 °C for 3 or 4 days. Cells were fixed
with 1% paraformaldehyde and stained with 0.5% crystal violet.
Cells were solubilized with 1% SDS and the absorbance at 590
nm was determined.
Immunoblotting—PAGE and immunoblotting were performed as described previously (18). Gel samples were reduced
with 2% ␤-mercaptoethanol. Immunoblots were incubated
with primary antibody in TBS-T (20 mM Tris, pH 7.6, 137 mM
NaCl, 0.1% Tween 20) containing 1% bovine serum albumin
followed by goat anti-rabbit or -mouse horseradish peroxidaselinked secondary antibody. Blots were developed using ECL
(Pierce). After detection, blots were stripped by incubation with
0.2 M glycine, 0.1% SDS, 1% Tween, pH 4.0 (35). Blots were then
washed, reblocked, and reprobed.
Statistical Analysis—Data are expressed as mean ⫾ S.E. and
represent one of at least two independent experiments performed in triplicate (cell area) or in quadruplicate (cell growth
and collagen gel contraction). Statistical significance was determined using either one-way analysis of variance with Turkey’s
post-test or Student’s t test for unpaired samples using Prism
software (GraphPad Software, San Diego, CA). Differences less
than 0.05 were considered significant.
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FIGURE 2. Localization of the heparin-binding and growth-promoting
activities of FNIII1. A, glutathione-coated plates were incubated with saturating concentrations of the various fusion proteins. Binding of biotin-heparin was assayed by enzyme-linked immunosorbent assay. Data represent the
mean absorbance of triplicate wells ⫾ S.E. *, significantly different from
⫹GST, p ⬍ 0.01. B, FN-null MFs were seeded on collagen-coated wells. Four
hours after seeding, cells were treated with 400 nM of the various fusion proteins and cell number was determined at various times as described under
“Experimental Procedures.” Data are presented as the absorbance obtained
at 590 nm and represent the mean ⫾ S.E. Maximal growth in response to
GST/III1H,8 –10 occurs with 100 nM protein (32). ⫹GST/III1H,8 –10, ⫹GST/
III1H,8 –10⌬RWR, and ⫹GST/III1H,8 –10RGE are significantly different from
⫹PBS on days 2, 3, and 4, p ⬍ 0.01.

Mutating Arg613, Trp614, and Arg615 in GST/III1H,8 –10 to
the corresponding, non-charged amino acid sequence in FNIII7
(Thr1178-Thr1179-Thr1180) resulted in a partial decrease in the
heparin-binding activity of the construct (GST/III1H,8 –
10⌬RWR; Fig. 2A). Mutating two additional residues in GST/
III1H,8 –10⌬RWR (K609G and K617A; GST/III1H,8 –
10⌬KRWRK) abolished the heparin-binding activity (Fig. 2A),
as well as the growth response to GST/III1H,8 –10 (Fig. 2B).
Mutating the integrin-binding RGD sequence in FNIII10 to
RGE only partially inhibited the growth response (Fig. 2B),
underscoring the importance of FNIII1H in the cellular
response to the matrix mimetic.
Studies utilizing overlapping peptides extending from Lys609
to Thr627 were conducted next to confirm the importance of
this region in fibronectin and GST/III1H,8 –10-induced
growth. Addition of FNIII1 Peptides 5 or 6 to cells blocked the
increase in growth induced by either GST/III1H,8 –10 (Fig. 3A)
or fibronectin (Fig. 3B). In contrast, Peptide 7 had no effect on
fibronectin- or GST/III1H,8 –10-induced growth (Fig. 3, A and
B). Peptides 5 and 6 did not affect cell growth in the absence of
fibronectin (not shown). A schematic of the FNIII1 peptides
used in this study is shown in Fig. 3C. Taken together, these
data identify Arg613, Trp614, Arg615, and Lys617 as the novel
heparin-binding and growth-promoting site in FNIII1.
NOVEMBER 17, 2006 • VOLUME 281 • NUMBER 46

FIGURE 3. Effect of FNIII1 peptides on fibronectin-induced cell growth.
FN-null MFs were seeded on collagen-coated wells. Four hours after seeding,
cells were treated with (A) GST/III1H,8 –10 (100 nM), (B) fibronectin (FN; 40 nM),
or an equal volume of PBS (Cntl), in the absence (“no addition”) and presence
of FNIII1 peptides (shown in mM). Following a 3-day incubation, cell number
was determined. Data are presented as the absorbance obtained at 590 nm
and represent the mean ⫾ S.E. A, *, significantly different from ⫹GST/III-1H,8 –
10, p ⬍ 0.01. B, *, significantly different from ⫹FN, p ⬍ 0.001. Peptide
sequences are shown in C.

Localization of the Epitopes for the Function-blocking AntiFNIII1 Antibody, 9D2—The 9D2 mAb binds to FNIII1 and
blocks fibronectin matrix assembly (29). As such, 9D2 has been
used in several studies to distinguish the effects of soluble
fibronectin from those of ECM fibronectin. 9D2 inhibits
fibronectin-stimulated cell growth (3), contractility (8), and
migration (7). 9D2 mAb does not block the initial association of
fibronectin with cell surfaces (29), nor does it block cell adhesion to fibronectin (7). These studies suggest that the 9D2
epitope may be located at or near the matricryptic heparinJOURNAL OF BIOLOGICAL CHEMISTRY
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nus of FNIII1 (GST/III1I597) did
not alter 9D2 recognition (Fig. 4A).
In contrast, removal of both F and G
␤-strands (GST/III1Y646) resulted
in loss of 9D2 recognition (Fig. 4A),
indicating that the 9D2 epitope is
contained within the C-F ␤ strands.
It was proposed previously that
Lys641 of human fibronectin is part
of the 9D2 epitope, as rat fibronectin, which contains Thr at this site,
is not recognized by 9D2 (29). Lys641
is located within the loop connecting ␤ strands E and F (25). Indeed,
mutating Lys641 to Thr in GST/III1
resulted in loss of 9D2 recognition
(GST/III1K641T; Fig. 4B), demonstrating a role for Lys641 in 9D2
binding to human fibronectin.
We next used the mutated GST/
III1H,8 –10 constructs to ask
FIGURE 4. Localization of the 9D2 epitope in FNIII1. In A–C, aliquots (0.2 g) of GST/III1 fusion proteins were whether the cryptic heparin-bindelectrophoresed on 10 or 12% polyacrylamide gels and analyzed by immunoblotting (IB) with the anti-FNIII1 ing site, located within the C
antibody, 9D2. Blots were then stripped and reprobed for GST. Molecular mass markers are indicated to the left.
In D, glutathione-coated plates were incubated with saturating concentrations of the various fusion proteins. ␤-strand of FNIII1, is also part of the
Binding of 9D2, mouse IgG, and anti-GST antibodies was assayed by enzyme-linked immunosorbent assay. 9D2 epitope. As shown in Fig. 4C,
Data represent the mean absorbance of quadruplicate wells ⫾ S.E.
GST/III1H,8 –10 was recognized by
9D2 in immunoblots. In contrast,
9D2 did not immunoblot either GST/III1H,8 –10⌬RWR or
GST/III1H,8 –10⌬KRWRK (Fig. 4C). Identical results were
obtained when the constructs were analyzed by enzyme-linked
immunosorbent assay (Fig. 4D). These results indicate that residues Arg613, Trp614, and Arg615 are important components of
the 9D2 epitope. Consistent with these findings, cell growth in
response to GST/III1H,8 –10 was inhibited by 9D2 IgG, but not
non-immune IgG (Fig. 5).
ECM Fibronectin Increases Cell Area—Cell growth has been
positively correlated with total cell area (37). Thus, one mechanism by which GST/III1H,8 –10 may promote cell growth, as
well as cell migration, is by increasing cell area. To analyze the
effects of the matrix mimetic on cell area, FN-null MFs were
seeded onto collagen I-coated dishes and incubated for 4 h to
allow basal cell spreading to occur. FN-null MFs are grown
under serum-free conditions, providing an ideal system for
determining cell area in the complete absence of fibronectin,
FIGURE 5. 9D2 blocks cell growth in response to GST/III1H,8 –10. FN-null and for distinguishing the effects of soluble versus matrix
MFs were seeded on collagen-coated wells. Four hours after seeding, cells fibronectin (3, 8, 9, 32, 38). In the absence of GST/III1H,8 –10,
were treated with either 100 nM GST or GST/III1H,8 –10 in the presence of 9D2
(500 nM) or non-immune IgG (500 nM), or an equal volume of PBS. Following a the average area of collagen-adherent cells 4 h after seeding was
2
3-day incubation, cell number was determined. Data are presented as the ⬃900 m , indicating that cells were well spread on the colla-fold increase in cell number over control (⫹GST ) and represent the mean ⫾ gen substrate (39 – 41). Cells were then treated with GST/
S.E. of 1 of 2 experiments performed in quadruplicate. *, significantly different
III1H,8 –10, fibronectin, or control fusion proteins for an addifrom “GST/III1H,8 –10⫹IgG, ” p ⬍ 0.05.
tional 2 h. As shown in Fig. 6A, addition of either GST/
binding site. To localize the 9D2 epitope, a series of truncated III1H,8 –10 or intact fibronectin to collagen-adherent cells
FNIII1 constructs were produced and analyzed by immunoblot- increased cell area. Cell spreading was not increased in
ting. As shown in Fig. 4A, sequential removal of C-terminal response to a construct in which the heparin-binding III13
residues comprising either the connecting sequence to FNIII2 module was substituted for III1H (GST/III8 –10,13; Fig. 6A),
(GST/III1F666), or the G ␤-strand of FNIII1 (GST/III1F664 demonstrating the specificity of the III1H fragment. Similarly,
(36) and GST/III1Y656 (25)) had no effect on 9D2 recognition. treatment of cells with a construct in which the III2– 4 modules
Similarly, removal of both A and B ␤-strands from the N termi- were substituted for III8 –10 did not increase cell area (GST/

Heparin-binding and Growth Activities of Fibronectin III1

III1H,2– 4; Fig. 6A), suggesting that integrin ligation is necessary for the cell spreading response. However, treatment of cells
with an integrin-binding fragment in which the III1H fragment
was absent (GST/III8 –10; Fig. 6A) also failed to increase cell
area, further demonstrating a role for III1H in regulating cell
area.
Our studies indicate that FNIII1H contributes to cell spreading and that a portion of the 9D2 epitope lies within the functional heparin-binding domain of FNIII1. Furthermore, 9D2
mAb blocks both cell growth (3) and migration (7) in response
to fibronectin. Thus, to determine whether 9D2 inhibits cell
spreading in response to fibronectin, FN-null MFs were
allowed to spread on a collagen substrate and then treated with
fibronectin in the presence of either 9D2 or non-immune IgG.
As shown in Fig. 6B, fibronectin triggered a significant increase
in projected cell area 2 and 24 h after its addition. Furthermore,
NOVEMBER 17, 2006 • VOLUME 281 • NUMBER 46
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FIGURE 6. The ECM form of fibronectin increases cell area. FN-null MFs
were allowed to adhere and spread on collagen I-coated wells for 4 h.
A, cells were then treated for 2 h with 250 nM of the various fusion proteins.
In B, cells were treated for 2 or 24 h with 20 nM FN in the presence of either
50 g/ml non-immune mouse IgG or 50 g/ml anti-FNIII1, 9D2. Control
cells were treated with PBS only. Cells were then fixed and phase-contrast
images were obtained. Cell areas were determined as described under
“Experimental Procedures.” Data are presented as mean cell area (m2) ⫾ S.E.
of at least 70 cells per condition and represent 1 of 2 experiments performed.
A, *, significantly different from “⫹PBS,” p ⬍ 0.05. B, *, “⫹FN⫹9D2” is significantly different from “⫹FN⫹IgG,” p ⬍ 0.05.

the increase in cell area in response to fibronectin was blocked
by addition of 9D2 mAb, providing evidence that fibronectin
matrix assembly and exposure of the matricryptic site in FNIII1
are required for the increase in cell area.
Fibronectin Increases Cell Area by Transiently Increasing the
Rate of Cell Spreading—To analyze the kinetics of fibronectininduced cell spreading, collagen-adherent FN-null cells were
treated with either fibronectin or an equal volume of PBS for
various times and projected cell areas were determined. As
shown in Fig. 7, fibronectin triggered a rapid increase in cell
area that was evident within 10 min of its addition. This
increase in cell spreading was followed by a plateau phase that
began ⬃1 h after fibronectin addition and continued for ⬃4 h
(Fig. 7A). Following the plateau phase, cell spreading resumed
at a rate similar to that observed with control (PBS-treated)
cells (Fig. 7, A and C). Linear regression analysis (r2 ⱖ 0.8) was
used to determine the rate of cell spreading immediately after
fibronectin addition (⬍1 h; Fig. 7B) and following the plateau
phase (4 –24 h after fibronectin treatment; Fig. 7C). As shown in
Fig. 7D, fibronectin transiently increased the rate of cell spreading from 103.7 (1.7 m2/min) to 632.4 m2/h (10.5 m2/min).
Following the plateau phase, the rate of cell spreading of
fibronectin-treated cells returned to a rate similar to that
observed in PBS-treated cells (66.8 versus 54.0 m2/h, respectively; Fig. 7D). In contrast, the early and late phases of cell
spreading of PBS-treated control cells were not significantly
different (Fig. 7D). These data indicate that addition of
fibronectin to collagen-adherent cells triggers a rapid yet transient increase in the rate of cell spreading.
Relationship between Cell Area and Growth—We next
analyzed the effects of mutant heparin- and integrin-binding
GST/III1H,8 –10 constructs on cell spreading to (i) identify
the amino acid residues responsible for increasing cell area
and (ii) determine whether changes in cell area paralleled
changes in cell growth. Addition of the FNIII1 heparin-binding mutant, GST/III1H,8 –10⌬KRWRK, to collagen-adherent FN-null MFs did not increase cell area (Fig. 8A) and
likewise, did not enhance cell growth (Fig. 8B). Similarly,
both the cell spreading response (Fig. 8A) as well as the cell
growth response (Fig. 8B) to GST/III1H,8 –10 was abolished
by mutating the integrin-binding sequences in FNIII8 –10
(GST/III-1H,8 –10⌬Syn/RGE). Together, these data indicate
that cell area and growth are co-regulated by the heparinbinding activity of FNIII1 and the integrin-binding activity of
FNIII8 –10. Treatment of cells with a construct in which only
the integrin-binding synergy site in FNIII9 was mutated
(GST/III1H,8 –10⌬Syn) stimulated cell spreading (Fig. 8A)
and cell growth (Fig. 8B) to a similar extent as GST/III1H,8 –
10. These data suggest that for cells adherent to collagen I,
increased cell spreading in response to the fibronectin
matrix mimetic is correlated with enhanced cell growth.
To determine whether GST/III1H,8 –10 can increase the
area and growth of cells adherent to other ECM substrates,
FN-null cells were seeded on various adhesive proteins and
allowed to adhere and spread for 4 h. Vitronectin was used at a
non-saturating concentration to avoid inducing maximal cell
area prior to GST/III1H,8 –10-treatment. In all experiments,
wells were blocked with bovine serum albumin to eliminate
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adhesion of GST/III1H,8 –10 to the tissue culture plastic. Cells
seeded in bovine serum albumin-coated wells in the presence of
soluble GST/III1H,8 –10 are non-adherent (not shown). As
shown in Fig. 9A, GST/III1H,8 –10 stimulated an increase in
cell area when cells were adherent to several different ECM
proteins, including fibrinogen, vitronectin, and laminin. Furthermore, this increase in cell area was accompanied by a similar increase in cell growth (Fig. 9B).
Cell Area Expansion Is Not Required for GST/III1H,8 –10induced Growth—Cell spreading may physically trigger local
changes in cytoskeletal conformation that in turn, allow for the
recruitment and activation of signaling complexes involved in
cell proliferation (42– 44). As such, the relative change in cell
area induced by ECM fibronectin may serve to mechanically
stimulate the local activation of intracellular signals involved
in cell growth control. To determine whether a change in cell
area is required for enhanced cell growth in response to
GST/III1H,8 –10, cell area expansion in response to GST/
III1H,8 –10 was limited by seeding FN-null MFs on wells
coated with saturating amounts of fibronectin or vitronec-
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tin. These conditions were used to promote maximal cell
spreading within the first 4 h of seeding. As shown in Fig.
10A, areas of cells adherent to either fibronectin or vitronectin were significantly greater than those of cells adherent to
collagen I and as anticipated, the areas of fibronectin- and
vitronectin-adherent cells did not increase in response to
GST/III1H,8 –10 (Fig. 10A). In contrast, the increase in cell
growth was still observed in response to GST/III1H,8 –10,
even in the absence of an increase in cell area (Fig. 10B).
These data indicate that an absolute increase in cell area is
not required for enhanced cell growth in response to GST/
III1H,8 –10 and suggest that ECM FN-induced growth is not
due to mechanical signals triggered in response to changes in
cell shape.

DISCUSSION
Fibronectin matrix polymerization promotes cellular functions critical for tissue repair, including cell growth (3– 6), cell
migration (7), and collagen matrix contraction (8). Fibronectin
matrix polymerization also promotes collagen I deposition (9,
VOLUME 281 • NUMBER 46 • NOVEMBER 17, 2006
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FIGURE 7. Fibronectin increases cell area by transiently increasing the rate of cell spreading. Fibronectin (20 nM) or an equal volume of PBS was added to
collagen-adherent FN-null cells as described in the legend to Fig. 6. At various times, cells areas were determined. A, representative time course of cell area in
response to fibronectin or PBS. Data are presented as mean cell area (m2) ⫾ S.E. of at least 49 cells per condition. The rate of cell spreading was determined
from the slope (B, m2/min; C, mm2/h) of the linear fit of the data. D, average cell spreading rates (m2/h) from four independent experiments. Data are
presented as mean ⫾ S.E. *, p ⬍ 0.05 versus other groups.
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10) and enhances the tensile strength of collagen-based tissue
constructs (11). The mechanism by which ECM fibronectin
exerts its unique effect on cell function is only partially understood. We previously hypothesized that conformational
changes during fibronectin matrix remodeling expose a “matricryptic,” heparin-binding activity in III1 that serves to trigger
cellular responses that are unique to ECM fibronectin. To test
this hypothesis, we produced a recombinant fibronectin construct in which the heparin-binding fragment of FNIII1 was
directly linked to the integrin-binding FNIII8 –10 modules
(GST/III1H,8 –10). We found that treatment of cells with GST/
III1H,8 –10 stimulates cell growth, contractility, and migration
to a similar extent as ECM fibronectin (7, 32). The interaction of
GST/III1H,8 –10 with cell surfaces appears to be mediated by
HSPGs (32).
In the present study, we extended this work by localizing the
functional heparin-binding site of FNIII1H to the basic amino
acids Arg613, Trp614, Arg615, and Lys617. The 609KYILRWRPK
sequence in FNIII1 is unique among the type III repeats of
NOVEMBER 17, 2006 • VOLUME 281 • NUMBER 46

fibronectin and is highly conserved among species (45).
Human, rat, and mouse fibronectin sequences are identical in
this region; Arg613 is substituted with a lysine in Xenopus and
bovine fibronectin. Cell spreading and growth in response to
the fibronectin matrix mimetic required the Lys609-Arg613Trp614-Arg615-Lys617 residues of FNIII1 as well as integrin ligation. Constructs containing single integrin-binding domain
mutations (GST/III1H,8 –10RGE and GST/III1H,8 –10⌬Syn)
retained the ability to promote cell growth, whereas the double
integrin-binding mutant, GST/III1H,8 –10⌬Syn/RGE, did not.
These findings suggest that ligation of ␣5␤1 integrins by either
the RGD site in FNIII10 or the synergy site in FNIII9 is sufficient
to promote cell growth when coupled with FNIII1 binding to its
receptor. These results indicate that an ␣5␤1-dependent, but
RGD-independent, response can by stimulated by ECM
fibronectin. These results are consistent with previous observations that ECM fibronectin can stimulate cell growth by an
RGD-independent, heparin-dependent mechanism (38). Interestingly, cell growth in response to GST/III1H,8 –10 requires
that the III1H module be co-expressed with III8 –10 (32), suggesting that a physical interaction between the FNIII1 HSPG
receptor and ␣5␤1 integrins may be necessary for the integrinmediated response.
Our data suggest that the heparin-binding site of FNIII1 can
enhance ␣1␤1/␣2␤1 responses, as seen in collagen gel contracJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 8. Cell area expansion and growth require both integrin- and heparin-binding activities. FN-null MFs were allowed to adhere and spread on
collagen I-coated wells for 4 h. Cells were then treated with 250 nM of the
various GST/III1H,8 –10 constructs. A, 2 h after treatment, cells were fixed and
areas were determined as described in the legend to Fig. 6. Data are presented as mean cell area (m2) ⫾ S.E. of at least 50 cells per condition. B, 4
days after addition of recombinant proteins, cells were fixed and cell number
was determined. Data are presented as -fold increase in cell number over
control (growth in the presence of GST). *, p ⬍ 0.05 versus GST.

FIGURE 9. Effect of GST/III1H,8 –10 on the area and growth of cells adherent to various ECM substrates. FN-null MFs were seeded on wells coated
with collagen (COL), fibrinogen (FBG), vitronectin (VN; 1 g/ml), or laminin
(LN) and incubated for 4 h. Cells were then treated for an additional 2 h (A) or
4 days (B) with 250 nM GST/III1H,8 –10 or GST. Cell area and growth were
determined as described in the legend to Fig. 6. Data are presented as
mean ⫾ S.E. of two independent experiments. *, p ⬍ 0.05 versus GST control.
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tion assays presented in Fig. 1A, as well as ␣5␤1-mediated
responses, as observed in the cell spreading and growth
response to GST/III1H,8 –10 (Fig. 8). The mechanism by which
FNIII1 modulates ␤1 integrin function is currently unknown.
HSPGs are known to function as co-receptors to modify integrin-mediated responses (46). A recombinant fibronectin construct containing both the C-terminal heparin-binding III13
module and the integrin-binding III7–11 domain (GST/III7–
11,13) supports cell spreading and stress fiber formation when
applied as an adhesive substrate (47). In the present study, we
utilized a similar construct (GST/III8 –10,13) to assess the
specificity of the FNIII1H module in enhancing cell area. When
added in solution, GST/III8 –10,13 did not increase the area of
cells previously spread on a collagen substrate, consistent with
the observation that GST/III8 –10,13 is also unable to promote
collagen gel contraction or enhance cell growth (32). The
increase in cell area in response to fibronectin was associated
with morphological changes indicative of a switch from isotropic to anisotropic cell spreading (results not shown). As such,
distinct intracellular mechanisms may control cell area immediately following cell attachment to substrate-bound fibronectin monomers, where isotropic spreading and FNIII13 signaling
predominate (47), versus during fibronectin matrix formation
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FIGURE 10. Cell area expansion is not required for GST/III1H,8 –10-induced growth. FN-null MFs were seeded on wells coated with collagen (COL),
fibronectin (FN), or vitronectin (VN; 10 g/ml) and incubated for 4 h. Cells
were then treated for an additional 2 h (A) or 4 days (B) with 250 nM GST/
III1H,8 –10 or GST. Cell area and growth were determined as described in the
legend to Fig. 6. Data are presented as mean ⫾ S.E. of four independent
experiments. *, p ⬍ 0.05 versus GST control.

or remodeling, when anisotropic spreading and FNIII1 signaling occur. The downstream effects of both FNIII13 and FNIII1H
are mediated by HSPGs (32, 47, 48). As such, additional interactions, possibly involving the core protein of proteoglycans
(46), may contribute to the subsequent generation of distinct
intracellular signals that modulate cell spreading. The dissimilar effects of GST/III1H,8 –10 and GST/III8 –10,13 on cytoskeletal reorganization and cell spreading may also result from their
different subcellular localization, as GST/III1H,8 –10 co-localizes with HSPGs in lipid rafts, whereas GST/III8 –10,13 localizes to focal contacts (32). A similar partitioning of the syndecan and glypican families of HSPGs has been observed (46, 49).
Fibronectin increased cell area by transiently increasing the
rate of cell spreading from 103.7 to 632.4 m2/h. These results
are consistent with previous data obtained from laminin-adherent hepatocytes that demonstrated an initial spreading rate
of 740 m2/h (34). The rapid increase in cell area in response
to fibronectin, combined with our data indicating a role for
the ECM form of fibronectin in cell spreading, suggests that
FNIII1-mediated responses arise from early changes in
fibronectin conformation that are initiated upon binding of
fibronectin to the cell surface (20), and not from the formation of extensive fibronectin fibrils per se. The increase in cell
area in response to fibronectin and GST/III1H,8 –10 is
accompanied by the formation of lamellopodia (not shown).
Hence, it is likely that enhanced cell spreading and lamellopodia formation are key steps that mediate the increased
rates of cell migration observed in response to ECM
fibronectin and GST/III1H,8 –10 (7).
Actin polymerization provides the driving force for cell
spreading (50), whereas membrane tension generated by membrane-cytoskeletal adhesions (51) restricts spreading (42).
Therefore, the appearance of a plateau following the rapid
increase in cell area of fibronectin-treated cells may indicate
that cells have reached a maximal area. Similarly, for cells
spread on fibronectin or vitronectin, the absence of an increase
in cell area in response to GST/III1H,8 –10 may be due to the
limitation of cell area. Approximately 4 h after the initiation of
the plateau phase, spreading of fibronectin-treated cells
resumed at a rate similar to control (PBS-treated) cells. The
stimulus that reinitiated cell spreading is not known, but may
be related to increased cell mass and/or renewed availability of
adhesion receptors (41).
Several studies have provided evidence that changes in cell
growth are tightly coupled to changes in cell area (37, 52). Others suggest that cell spreading may serve a permissive role for
integrin-mediated proliferation (53). During cell spreading,
changes in the conformation of the actin cytoskeleton may
physically recruit and/or cluster signaling molecules that regulate cell growth (44). Our data indicate that whereas ECM FN
can promote cell spreading, increased cell area is not the mechanism by which ECM fibronectin increases the rate of cell
growth. Moreover, our data provide evidence that under certain circumstances, increased cell growth can be uncoupled
from changes in cell area. These findings are important for
understanding mechanisms that control ECM fibronectin-induced cell growth in vivo, as the inability to increase cell area
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and hence, cytoskeletal tension (42), in intact tissue may normally serve to limit the cellular response to growth signals.
The amino acid residues involved in GST/III1H,8 –10-induced cell spreading and growth, Arg613-Trp14-Arg615, contribute to the 9D2 epitope. Furthermore, 9D2 blocks GST/
III1H,8 –10-stimulated cell growth as well as fibronectininduced cell spreading. The 9D2 antibody has been shown to
inhibit several other fibronectin-stimulated cell functions,
including cell growth (3), cell migration (7), and collagen gel
contraction (8). 9D2 mAb inhibits fibronectin matrix polymerization in a variety of cell types including dermal fibroblasts
(29), aortic smooth muscle cells (9), microvascular endothelial
cells (9), as well as the FN-null myofibroblasts (3). 9D2 mAb
does not block fibronectin matrix polymerization in small airway epithelial cells, but does inhibit migration (7), suggesting
that 9D2 affects migration in these cells by directly blocking the
Arg613-Trp614-Arg15 site in ECM fibronectin. Taken together,
these data support the hypothesis that ECM fibronectin regulates cell behavior, in part, through the cell-dependent exposure of a neoepitope within the conformationally labile FNIII1
module. Decreasing intracellular cytoskeletal tension preferentially reduces the appearance of an FNIII1 epitope (30), suggesting that exposure of the matricryptic site in FNIII1 may be
dynamically regulated. If so, reduced cellular tension on ECM
fibrils may impair tissue remodeling by “closing” matricryptic
FNIII1 sites that would normally stimulate cell growth, collagen
fibril contraction, and re-epithelialization of injured tissues.
Novel therapeutic approaches that provide injured cells with
synthetic fibronectin matrix mimetics may circumvent either
diminished fibronectin matrix assembly or decreased expression of matricryptic FNIII1 sites and hence, accelerate wound
repair by providing tissues with ECM fibronectin-specific
signals.
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